People: Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

9.28USD
4:00pm EDT
Change (% chg)

$0.16 (+1.75%)
Prev Close
$9.12
Open
$9.04
Day's High
$9.35
Day's Low
$8.91
Volume
218,560
Avg. Vol
205,353
52-wk High
$18.25
52-wk Low
$7.58

Search Stocks

Fyfe, Gwendolyn 

Dr. Gwendolyn A. Fyfe, M.D., serves as Independent Director of Infinity Pharmaceuticals Inc., since March 8, 2012. From 1997 to 2009Dr. Fyfe held various positions with Genentech, Inc. (now a member of the Roche Group), a publicly traded biopharmaceutical company, including Vice President, Oncology Development; Vice President, Avastin® Franchise Team; as well as the honorary title of Senior Staff Scientist. Dr. Fyfe played an important role in the development of Genentech’s approved oncology agents including Rituxan®, Herceptin®, Avastin® and Tarceva®. Dr. Fyfe sat on the development oversight committee for all of Genentech’s products and participated in the Research Review Committee that moved products from research into clinical development. Since leaving Genentech in 2009, Dr. Fyfe has been a consultant for venture capital firms and for a variety of biotechnology companies. Dr. Fyfe serves on the board of directors of Array BioPharma, Inc., a publicly traded biopharmaceutical company, and Igenica, Inc., a privately held biopharmaceuticals company, and previously served on the board of Pharmacyclics, Inc., a publicly traded biopharmaceutical company, during the last five years. Dr. Fyfe is a recognized oncology expert in the broader oncology community and has been an invited member of Institute of Medicine panels, National Cancer Institute working groups and grant committees and American Society of Clinical Oncology oversight committees. She received her M.D. from Washington University School of Medicine and is a board certified pediatric oncologist. We believe Dr. Fyfe’s qualifications to serve on our board of directors include her substantial industry experience in the late-stage development and regulatory approval processes for novel oncology therapeutics.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Adelene Perkins

1,635,480

Lawrence Bloch

813,477

Julian Adams

1,179,840

Winston Lam

--

Sujay Kango

--

Vito Palombella

801,226
As Of  30 Dec 2014
Search Stocks